| Title |
Effect of eprosartan-based therapy on systolic blood pressure and total cardiovascular risk in a large international population: preliminary report of the observational POWER study
|
|---|---|
| Published in |
Vascular Health and Risk Management, September 2012
|
| DOI | 10.2147/vhrm.s34834 |
| Pubmed ID | |
| Authors |
Assen Goudev, Jean-Pascal Berrou, Atul Pathak |
| Abstract |
Estimation of total cardiovascular risk is useful for developing preventive strategies for individual patients. The POWER (Physicians' Observational Work on Patient Education According to their Vascular Risk) survey, a 6-month, open-label, multinational, post-marketing observational evaluation of eprosartan, an angiotensin II receptor blocker, was undertaken to assess the efficacy and safety of eprosartan-based therapy in the treatment of high arterial blood pressure in a large population recruited from 16 countries with varying degrees of baseline cardiovascular risk, and the effect of eprosartan-based therapy on total cardiovascular risk, as represented by the SCORE (Systematic Coronary Risk Assessment) or Framingham risk equations. |
X Demographics
The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 1 | 100% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Practitioners (doctors, other healthcare professionals) | 1 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 30 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 1 | 3% |
| Unknown | 29 | 97% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Master | 6 | 20% |
| Student > Bachelor | 6 | 20% |
| Student > Doctoral Student | 3 | 10% |
| Student > Ph. D. Student | 2 | 7% |
| Other | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 10 | 33% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 9 | 30% |
| Nursing and Health Professions | 3 | 10% |
| Social Sciences | 2 | 7% |
| Agricultural and Biological Sciences | 1 | 3% |
| Chemical Engineering | 1 | 3% |
| Other | 2 | 7% |
| Unknown | 12 | 40% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2012.
All research outputs
#20,823,121
of 25,584,565 outputs
Outputs from Vascular Health and Risk Management
#663
of 785 outputs
Outputs of similar age
#148,262
of 188,508 outputs
Outputs of similar age from Vascular Health and Risk Management
#10
of 11 outputs
Altmetric has tracked 25,584,565 research outputs across all sources so far. This one is in the 10th percentile – i.e., 10% of other outputs scored the same or lower than it.
So far Altmetric has tracked 785 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 9.5. This one is in the 7th percentile – i.e., 7% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 188,508 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 9th percentile – i.e., 9% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 11 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.